Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergencies for those above the age of 18 years.
The Central Drugs Standard Control Organisation (CDSCO) gave its nod to the vaccine for use as both primary series as well as a heterologous booster.
In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.
In a statement, Bharat Biotech said that the intranasal vaccine iNCOVACC had proven to be safe during clinical trials. The company said the vaccine was tested both as a primary dose and as a heterologous booster dose, but no efficacy data has been provided yet. iNCOVACC will become the first intranasal vaccine in the world.
"Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered COVID vaccines in India," Bharat Biotech said in a statement.
"iNCOVACC has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics," the company added.
COVID-19 Was Not A Lab Leak, Emerged From Animal Market, New Research Shows Karnataka Forms Special Team To Probe 'Covid Scam' During BJP Rule The Science Behind Long COVID: Understanding The Persistent Presence Of SARS-CoV-2 Proteins Amazon Employee Greets Friend At Wedding, Dies Of Cardiac Arrest "Speculative, Inaccurate": Canada Factchecks Own Media Over India Charge This Asian City Is Emerging As Sex Tourism Hub. It's Not Where You Think Most And Least Expensive Passports In 2024: Here's Where India Stands Advanced H5N1 Kit To Help In Early, Rapid Detection Of Bird Flu Who Is Pam Bondi, Trump's Choice For Top Lawyer After Matt Gaetz Withdrawal Track Latest News Live on NDTV.com and get news updates from India and around the world.